Eyeworld

Indication and Usage RESTASIS ® (cyclosporine ophthalmic emulsion) 0.05% is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular infl ammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-infl ammatory drugs or using punctal plugs. Important Safety Information Contraindications RESTASIS ® is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation. Warnings and Precautions Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, individuals prescribed RESTASIS ® should not touch the vial tip to their eye or other surfaces. Use With Contact Lenses: RESTASIS ® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS ® ophthalmic emulsion. Adverse Reactions In clinical trials, the most common adverse reaction following the use of RESTASIS ® was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring). Please see Brief Summary of the full Prescribing Information on adjacent page. THE DRY EYE TREATMENT SHE NEEDS TODAY. BECAUSE TOMORROW MATTERS. RESTASIS ® twice a day, every day, helps patients experience increased tear production Increased tear production was seen at 6 months. 1 ©2015 Allergan, Inc., Irvine, CA 92612 Æ marks owned by Allergan, Inc. APC21CL15 150302 Reference: 1. RESTASIS ® Prescribing Information. For patients with decreased tear production presumed to be due to ocular infl ammation associated with Chronic Dry Eye

• Cover